Brokerages Set Cellebrite DI Ltd. (NASDAQ:CLBT) PT at $20.29

Cellebrite DI Ltd. (NASDAQ:CLBTGet Free Report) has received a consensus recommendation of “Buy” from the eight analysts that are presently covering the company, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $20.29.

Several brokerages recently issued reports on CLBT. JPMorgan Chase & Co. boosted their price target on shares of Cellebrite DI from $21.00 to $22.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Craig Hallum increased their target price on Cellebrite DI from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Bank of America lifted their price target on Cellebrite DI from $13.00 to $17.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Deutsche Bank Aktiengesellschaft upped their price target on Cellebrite DI from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Finally, Needham & Company LLC upped their target price on shares of Cellebrite DI from $17.00 to $21.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th.

Check Out Our Latest Stock Analysis on Cellebrite DI

Cellebrite DI Stock Down 2.3 %

Shares of NASDAQ:CLBT opened at $19.72 on Monday. The company has a 50-day moving average price of $17.97 and a 200-day moving average price of $14.85. Cellebrite DI has a 12 month low of $7.91 and a 12 month high of $21.00.

Cellebrite DI (NASDAQ:CLBTGet Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. The business had revenue of $106.90 million during the quarter, compared to analyst estimates of $102.06 million. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. Cellebrite DI’s quarterly revenue was up 27.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.09 EPS. Equities analysts expect that Cellebrite DI will post 0.32 earnings per share for the current year.

Institutional Trading of Cellebrite DI

A number of institutional investors have recently made changes to their positions in the stock. Janney Montgomery Scott LLC boosted its holdings in Cellebrite DI by 240.1% in the first quarter. Janney Montgomery Scott LLC now owns 45,300 shares of the company’s stock worth $502,000 after purchasing an additional 31,981 shares during the last quarter. Sei Investments Co. raised its holdings in Cellebrite DI by 44.7% in the 1st quarter. Sei Investments Co. now owns 121,166 shares of the company’s stock worth $1,343,000 after purchasing an additional 37,408 shares during the period. Russell Investments Group Ltd. lifted its position in Cellebrite DI by 92.5% during the first quarter. Russell Investments Group Ltd. now owns 16,649 shares of the company’s stock valued at $188,000 after purchasing an additional 8,001 shares in the last quarter. PEAK6 Investments LLC purchased a new stake in Cellebrite DI in the 1st quarter worth approximately $319,000. Finally, Lazard Asset Management LLC increased its stake in shares of Cellebrite DI by 28.7% in the first quarter. Lazard Asset Management LLC now owns 21,697 shares of the company’s stock worth $240,000 after purchasing an additional 4,842 shares in the last quarter. Hedge funds and other institutional investors own 45.88% of the company’s stock.

About Cellebrite DI

(Get Free Report

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

See Also

Analyst Recommendations for Cellebrite DI (NASDAQ:CLBT)

Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.